Dimitri E. Grigoriadis Sells 71,775 Shares of Neurocrine Biosciences, Inc. (NBIX) Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Dimitri E. Grigoriadis sold 71,775 shares of the company’s stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $77.98, for a total transaction of $5,597,014.50. Following the transaction, the insider now owns 154,717 shares in the company, valued at approximately $12,064,831.66. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Neurocrine Biosciences, Inc. (NASDAQ NBIX) opened at $85.38 on Thursday. The company has a current ratio of 14.38, a quick ratio of 14.37 and a debt-to-equity ratio of 1.05. Neurocrine Biosciences, Inc. has a 52-week low of $39.21 and a 52-week high of $91.82. The stock has a market cap of $7,560.00, a PE ratio of -38.46, a price-to-earnings-growth ratio of 6.41 and a beta of 0.26.

Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings results on Tuesday, February 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.11). The business had revenue of $94.52 million for the quarter, compared to the consensus estimate of $94.00 million. During the same quarter in the previous year, the firm posted ($0.51) EPS. equities research analysts anticipate that Neurocrine Biosciences, Inc. will post -1.48 earnings per share for the current year.

NBIX has been the topic of several research reports. Needham & Company LLC reiterated a “buy” rating and set a $86.00 price target on shares of Neurocrine Biosciences in a research report on Thursday, November 2nd. Deutsche Bank reiterated a “buy” rating and set a $79.00 price target on shares of Neurocrine Biosciences in a research report on Thursday, November 2nd. Citigroup reiterated a “buy” rating and set a $79.00 price target on shares of Neurocrine Biosciences in a research report on Thursday, November 2nd. Piper Jaffray Companies reiterated a “buy” rating and set a $76.00 price target on shares of Neurocrine Biosciences in a research report on Wednesday, October 25th. Finally, Jefferies Group upped their target price on shares of Neurocrine Biosciences to $105.00 and gave the company a “buy” rating in a research report on Friday, January 5th. One analyst has rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. Neurocrine Biosciences presently has a consensus rating of “Buy” and a consensus price target of $89.53.

Several hedge funds have recently made changes to their positions in the company. The Manufacturers Life Insurance Company increased its stake in shares of Neurocrine Biosciences by 7.8% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock valued at $123,000 after acquiring an additional 193 shares during the last quarter. State Board of Administration of Florida Retirement System increased its stake in shares of Neurocrine Biosciences by 0.7% in the 3rd quarter. State Board of Administration of Florida Retirement System now owns 120,426 shares of the company’s stock valued at $7,380,000 after acquiring an additional 810 shares during the last quarter. Amalgamated Bank increased its stake in shares of Neurocrine Biosciences by 5.7% in the 4th quarter. Amalgamated Bank now owns 17,484 shares of the company’s stock valued at $1,357,000 after acquiring an additional 947 shares during the last quarter. Mutual of America Capital Management LLC increased its stake in shares of Neurocrine Biosciences by 0.9% in the 3rd quarter. Mutual of America Capital Management LLC now owns 112,862 shares of the company’s stock valued at $6,916,000 after acquiring an additional 1,036 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Neurocrine Biosciences by 25.5% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,904 shares of the company’s stock valued at $458,000 after acquiring an additional 1,200 shares during the last quarter.

TRADEMARK VIOLATION NOTICE: This news story was originally published by Week Herald and is the sole property of of Week Herald. If you are reading this news story on another site, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be accessed at https://weekherald.com/2018/02/15/dimitri-e-grigoriadis-sells-71775-shares-of-neurocrine-biosciences-inc-nbix-stock.html.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Insider Buying and Selling by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply